After mid-stage stumble, CRISPR pioneer searches for partner

18 November 2022
gene_genetic_test_biotech_biomarker_lab_research_2022_big

While  excitement about the potential of CRISPR/Cas9 gene editing remains high, a setback for a leading company using this technique shows it is no golden ticket to success.

Stock in Cambridge, USA-based Editas Medicine (Nasdaq: EDIT) dropped a tenth on Thursday and fell a further 4% after hours, after the unveiling of weak results from the Phase I/II BRILLIANCE trial.

Editas is using the study to evaluate its candidate EDIT-101 in the treatment of blindness due to the rare genetic disorder Leber congenital amaurosis 10 (LCA10).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology